Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 8/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14071841 | 0.97 | HCRTR1 (0.40) | HCRTR1HCRTR2LRRK2LMNAADRA2A | |
| SCHEMBL4406414 | 0.97 | HCRTR1 (0.40) | HCRTR1HCRTR2LRRK2LMNAADRA2A | |
| SCHEMBL29687401 | 0.97 | HCRTR1 (0.40) | HCRTR1HCRTR2LRRK2LMNAADRA2A | |
| SCHEMBL25541152 | 0.96 | LRRK2 (0.39) | HCRTR1HCRTR2LRRK2LMNAADRA2A | |
| SCHEMBL14071787 | 0.94 | HCRTR1 (0.42) | HCRTR1HCRTR2LRRK2LMNAADRA2A | |
| SCHEMBL4409498 | 0.94 | HCRTR1 (0.42) | HCRTR1HCRTR2LRRK2LMNAADRA2A | |
| SCHEMBL21840255 | 0.93 | HCRTR1 (0.39) | HCRTR1HCRTR2LRRK2LMNAADRA2A | |
| SCHEMBL21840256 | 0.93 | HCRTR1 (0.39) | HCRTR1HCRTR2LRRK2LMNAADRA2A | |
| SCHEMBL21352697 | 0.92 | LRRK2 (0.39) | HCRTR1HCRTR2LRRK2LMNAADRA2A | |
| SCHEMBL21352699 | 0.92 | LRRK2 (0.39) | HCRTR1HCRTR2LRRK2LMNAADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649250-B2 | Pyrrolobenzodiazepine conjugates | MEDIMMUNE LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11370801-B2 | Pyrrolobenzodiazepine conjugates | MEDIMMUNE LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| US-11370801-B2 | Pyrrolobenzodiazepine conjugates | MEDIMMUNE LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| EP-3668874-B1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LTD (GB) | 2021-12-22 | — | — | EP | disclosed |
| US-10799595-B2 | Pyrrolobenzodiazepine conjugates | MEDIMMUNE LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20200247823-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-20200115390-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2020-04-16 | — | — | US | disclosed |
| US-20200115390-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2020-04-16 | — | — | US | disclosed |
| US-20190282705-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| WO-2019034764-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| WO-2018069490-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282705-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | GABRE, GRIN2B, GABRB1 | HCRTR1 333/4885HCRTR2 183/4885LRRK2 2887/4885 |
| US-11649250-B2 | Pyrrolobenzodiazepine conjugates | CD79B, GABRG2, GABRA1 | HCRTR1 1168/4885HCRTR2 1037/4885LRRK2 4476/4885 |
| US-11370801-B2 | Pyrrolobenzodiazepine conjugates | NR0B2, HRH3, NR0B1 | HCRTR1 21/4885HCRTR2 7/4885LRRK2 3106/4885 |
| US-10799595-B2 | Pyrrolobenzodiazepine conjugates | GABRE, GRIN2B, GABRB1 | HCRTR1 333/4885HCRTR2 183/4885LRRK2 2887/4885 |
| US-20200115390-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | NR0B2, HRH3, NR0B1 | HCRTR1 21/4885HCRTR2 7/4885LRRK2 3106/4885 |
| US-20200247823-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | CD79B, GABRG2, GABRA1 | HCRTR1 1168/4885HCRTR2 1037/4885LRRK2 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.